ClinicalTrials.gg
CompletedNCT00492284RADICALUpdated Jun 2, 2011Results posted

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

A Phase 2 interventional study of verteporfin and verteporfin in Choroidal Neovascularization and Macular Degeneration, sponsored by QLT Inc.. Completed at 26 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-06-02.

Sponsored by QLT Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
16th of 45
162 · median 62
Started
2007
with 6 others
Phase 2
10 of 45
none open now
Registered
10th of 45
by date

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 16th largest by enrollment, is one of 7 that started in 2007, is one of 10 in phase 2, and was the 10th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis [within 2 hours] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy [within 2 hours]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.

03

Conditions studied

  • Choroidal Neovascularization
  • Macular Degeneration

Keywords

  • Macular Degeneration
  • AMD
  • CNV
  • Choroidal neovascularization
  • Photodynamic therapy
  • CNV Secondary to Age Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment naive for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye except for laser treatment outside the subfoveal area
  • Subfoveal CNV due to AMD
  • CNV must be = or >50 % of the entire lesion
  • All lesion composition types with a lesion greatest linear dimension (GLD) \< 5400 microns (approximately = or \<9 disc areas [DA])
  • Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA score) of 25 - 73 letters (approximate Snellen equivalent of 20/40 - 20/320), inclusive

Exclusion criteria

Exclusion Criteria:

  • Subfoveal geographic atrophy or subfoveal fibrosis of the study eye
  • Intraocular surgery within 3 months of enrollment
  • Inability to attend the protocol-required visits
  • Known allergies or to any of the study treatments.
  • Other systemic diseases or active uncontrolled infections that would make subject a poor medical risk
  • Uncontrolled glaucoma, defined as (1)subject is on >1 glaucoma medication (includes combination treatments) or (2)subject has glaucoma that could lead to progressive visual field deterioration
  • If subject has had a stroke within the last year
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    1/4 Fluence Triple Therapy

    Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter

    Drug: verteporfin · Drug: ranibizumab · Drug: dexamethasone

  • Experimental
    1/2 Fluence Triple Therapy

    Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter

    Drug: verteporfin · Drug: ranibizumab · Drug: dexamethasone

  • Experimental
    1/2 Fluence Double Therapy

    Reduced-fluence Visudyne followed by Lucentis double therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter

    Drug: verteporfin · Drug: ranibizumab

  • Experimental
    Ranibizumab

    Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter

    Drug: ranibizumab

Interventions

  • Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)

    Also known as: Visudyne, photodynamic therapy

  • Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)

    Also known as: Visudyne, photodynamic therapy

  • 0.5 mg intravitreal injection

    Also known as: Lucentis

  • 0.5 mg intravitreal injection

06

What researchers measure

Primary outcomes

  1. Mean Number of Retreatments (Day 0 Excluded)

    Retreatment was defined in the protocol as study treatment administered after Day 0. For the analyses of retreatment, any study treatment that was administered was considered to be a retreatment, and combination therapy was considered to be one retreatment, even though two or three treatment procedures were done. In the combination therapy groups, if a ranibizumab injection was given because retreatment was indicated and the previous combination treatment was less than 2 months before, the ranibizumab injection was counted as a retreatment.

    Time frame: Month 1 to Month 12

  2. Mean Change From Baseline in Study Eye Best-corrected VA Score (ETDRS Chart)

    Early Treatment Diabetic Retinopathy Study (ETDRS) method at 4 meters. Worst = 0; best = 100

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Mean Number of Retreatments (Day 0 Excluded)

    Retreatment was defined in the protocol as study treatment administered after Day 0. For the analyses of retreatment, any study treatment that was administered was considered to be a retreatment, and combination therapy was considered to be one retreatment, even though two or three treatment procedures were done. In the combination therapy groups, if a ranibizumab injection was given because retreatment was indicated and the previous combination treatment was less than 2 months before, the ranibizumab injection was counted as a retreatment.

    Time frame: Month 1 to Month 24

  2. Mean Change From Baseline in Study Eye Best-Corrected VA Score

    Early Treatment Diabetic Retinopathy Study (ETDRS) method at 4 meters. Worst = 0; best = 100

    Time frame: Baseline to Month 24

  3. Percentage of Subjects With >=15 Letters of Visual Acuity Gained From Baseline

    Time frame: Baseline to Month 12, Baseline to Month 24

  4. Percentage of Subjects With >=0 Letter Gain of Visual Acuity From Baseline

    Time frame: Baseline to Month 12, Baseline to Month 24

  5. Percentage of Subjects With >=15 Letters of Visual Acuity Lost From Baseline

    Time frame: Baseline to Month 12, Baseline to Month 24

  6. Mean Change From Baseline in Central Retinal Thickness

    Time frame: Baseline to Month 12, Baseline to Month 24

  7. Mean Change From Baseline in Lesion Size

    Mean change from baseline in lesion size measured as greatest linear dimension (GLD) of the lesion

    Time frame: Baseline to Month 12, Baseline to Month 24

07

Results

Posted Jun 22, 2010
Limitations and caveats
Retreatment and vision analysis limitations, sample size, lack of standard monotherapy regimen used in practice, no treatment regimen approved by regulatory authorities, potential for bias in FA assessment, no central reading center, single-masked

Participant flow

Participant flow — Overall Study
Milestone1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Started39394341
Completed38353731
Not completed14610
Withdrew: Adverse event0112
Withdrew: Lost to follow-up0031
Withdrew: Death0325
Withdrew: Withdrawal by subject1002

Outcome measures

PrimaryMean Number of Retreatments (Day 0 Excluded)

Retreatment was defined in the protocol as study treatment administered after Day 0. For the analyses of retreatment, any study treatment that was administered was considered to be a retreatment, and combination therapy was considered to be one retreatment, even though two or three treatment procedures were done. In the combination therapy groups, if a ranibizumab injection was given because retreatment was indicated and the previous combination treatment was less than 2 months before, the ranibizumab injection was counted as a retreatment.

Time frame:
Month 1 to Month 12
Reported as:
Mean · number of retreatments
Mean Number of Retreatments (Day 0 Excluded)
number of retreatments1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Mean Number of Retreatments (Day 0 Excluded)3.97 ± 3.123.00 ± 2.554.05 ± 2.935.39 ± 2.97
PrimaryMean Change From Baseline in Study Eye Best-corrected VA Score (ETDRS Chart)

Early Treatment Diabetic Retinopathy Study (ETDRS) method at 4 meters. Worst = 0; best = 100

Time frame:
Baseline to Month 12
Reported as:
Mean · Letters read on ETDRS chart
Mean Change From Baseline in Study Eye Best-corrected VA Score (ETDRS Chart)
Letters read on ETDRS chart1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Mean Change From Baseline in Study Eye Best-corrected VA Score (ETDRS Chart)3.6 ± 13.86.8 ± 13.45.0 ± 14.26.5 ± 15.5
SecondaryMean Number of Retreatments (Day 0 Excluded)

Retreatment was defined in the protocol as study treatment administered after Day 0. For the analyses of retreatment, any study treatment that was administered was considered to be a retreatment, and combination therapy was considered to be one retreatment, even though two or three treatment procedures were done. In the combination therapy groups, if a ranibizumab injection was given because retreatment was indicated and the previous combination treatment was less than 2 months before, the ranibizumab injection was counted as a retreatment.

Time frame:
Month 1 to Month 24
Reported as:
Mean · number of retreatments
Mean Number of Retreatments (Day 0 Excluded)
number of retreatments1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Mean Number of Retreatments (Day 0 Excluded)5.92 (4.35 to 7.49)4.34 (3.09 to 5.60)5.92 (4.46 to 7.38)8.68 (6.74 to 10.62)
SecondaryMean Change From Baseline in Study Eye Best-Corrected VA Score

Early Treatment Diabetic Retinopathy Study (ETDRS) method at 4 meters. Worst = 0; best = 100

Time frame:
Baseline to Month 24
Reported as:
Mean · Letters read on ETDRS chart
Mean Change From Baseline in Study Eye Best-Corrected VA Score
Letters read on ETDRS chart1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Mean Change From Baseline in Study Eye Best-Corrected VA Score-0.2 (-5.7 to 5.4)1.1 (-4.3 to 6.4)-0.3 (-6.2 to 5.6)4.4 (-1.5 to 10.2)
SecondaryPercentage of Subjects With >=15 Letters of Visual Acuity Gained From Baseline
Time frame:
Baseline to Month 12, Baseline to Month 24
Reported as:
Mean · Percentage of participants
Percentage of Subjects With >=15 Letters of Visual Acuity Gained From Baseline
Percentage of participants1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Baseline to Month 1225.6 (11.9 to 39.3)30.8 (16.3 to 45.3)25.6 (12.5 to 38.6)24.4 (11.2 to 37.5)
Baseline to Month 2420.5 (7.8 to 33.2)15.4 (4.1 to 26.7)16.3 (5.2 to 27.3)26.8 (13.3 to 40.4)
SecondaryPercentage of Subjects With >=0 Letter Gain of Visual Acuity From Baseline
Time frame:
Baseline to Month 12, Baseline to Month 24
Reported as:
Mean · Percentage of participants
Percentage of Subjects With >=0 Letter Gain of Visual Acuity From Baseline
Percentage of participants1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Baseline to Month 1264.1 (49.0 to 79.2)82.1 (70.0 to 94.1)69.8 (56.0 to 83.5)70.7 (56.8 to 84.7)
Baseline to Month 2461.5 (46.3 to 76.8)66.7 (51.9 to 81.5)60.5 (45.9 to 75.1)70.7 (56.8 to 84.7)
SecondaryPercentage of Subjects With >=15 Letters of Visual Acuity Lost From Baseline
Time frame:
Baseline to Month 12, Baseline to Month 24
Reported as:
Mean · Percentage of participants
Percentage of Subjects With >=15 Letters of Visual Acuity Lost From Baseline
Percentage of participants1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Baseline to Month 1212.8 (2.3 to 23.3)7.7 (0 to 16.1)11.6 (2.0 to 21.2)7.3 (0 to 15.3)
Baseline to Month 2420.5 (7.8 to 33.2)15.4 (4.1 to 26.7)20.9 (8.8 to 33.1)14.6 (3.8 to 25.5)
SecondaryMean Change From Baseline in Central Retinal Thickness
Time frame:
Baseline to Month 12, Baseline to Month 24
Reported as:
Mean · micron
Mean Change From Baseline in Central Retinal Thickness
micron1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Baseline to Month 12-115.9 ± 97.4-122.2 ± 104.8-137.8 ± 122.3-100.3 ± 90.1
Baseline to Month 24-110.2 ± 93.6-123.9 ± 97.1-121.0 ± 126.6-103.1 ± 99.1
SecondaryMean Change From Baseline in Lesion Size

Mean change from baseline in lesion size measured as greatest linear dimension (GLD) of the lesion

Time frame:
Baseline to Month 12, Baseline to Month 24
Reported as:
Mean · micron
Mean Change From Baseline in Lesion Size
micron1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Baseline to Month 1277.2 ± 960.3-20.4 ± 1550.7152.0 ± 1415.5-192.6 ± 672.5
Baseline to Month 2494.8 ± 865.1-103.3 ± 1326.1-112.5 ± 1209.4-205.3 ± 653.4

Adverse events

Collected over Month 0 to Month 24/last visit. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1/4 Fluence Triple Therapy—10/39 (25.6%)36/39 (92.3%)
1/2 Fluence Triple Therapy—13/39 (33.3%)36/39 (92.3%)
1/2 Fluence Double Therapy—15/43 (34.9%)36/43 (83.7%)
Ranibizumab—19/41 (46.3%)37/41 (90.2%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
Event1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
PneumoniaRespiratory, thoracic and mediastinal disorders1/393/390/433/41
Congestive Heart FailureCardiac disorders0/392/391/433/41
HypertensionCardiac disorders0/390/390/433/41
Accidental InjuryGeneral disorders0/392/391/431/41
Acute kidney failureRenal and urinary disorders0/392/390/432/41
Angina pectorisCardiac disorders0/392/391/430/41
SepsisGeneral disorders0/392/390/430/41
SyncopeCardiac disorders0/392/390/431/41
Atrial fibrillationCardiac disorders0/391/391/432/41
Breast carcinomaReproductive system and breast disorders0/391/390/432/41
Most frequent other events
Showing 10 of 82
Most frequent other events
Event1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumab
Chest painGeneral disorders2/391/392/431/1
Eye pain (study eye)Eye disorders7/399/399/4310/41
Accidental InjuryGeneral disorders6/395/397/439/41
Age-related Macular Degeneration progression (fellow eye)Eye disorders3/398/391/432/41
Vision abnormal (study eye)Eye disorders8/391/397/434/41
InfectionGeneral disorders7/397/395/438/41
HypertensionCardiac disorders7/392/397/435/41
Increased intraocular pressure (study eye)Eye disorders4/394/396/436/41
Urinary tract infectionRenal and urinary disorders2/393/394/436/41
Cataract (study eye)Eye disorders2/394/396/431/41

Baseline characteristics

Age Continuous
Age Continuous(years)1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumabTotal
Mean78 ± 878 ± 879 ± 679 ± 579 ± 7
Sex: Female, Male
Sex: Female, Male(Participants)1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumabTotal
Female2024232895
Male1915201367
Lesion composition
Lesion composition(participants)1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumabTotal
Minimally classic649827
Occult no classic1016201864
Predominantly classic2319141571
Central retinal thickness
Central retinal thickness(micron)1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumabTotal
Mean318.3 ± 95.9337.3 ± 106.8337.3 ± 121.4311.9 ± 95.5326.3 ± 105.4
Lesion size (greatest linear dimension)
Lesion size (greatest linear dimension)(micron)1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumabTotal
Mean2778.8 ± 1025.62740.1 ± 846.12796.1 ± 1122.83118.4 ± 1155.72860.1 ± 1049.4
Study Eye Best-corrected Visual Acuity Score (ETDRS chart)
Study Eye Best-corrected Visual Acuity Score (ETDRS chart)(Letters read on ETDRS chart)1/4 Fluence Triple Therapy1/2 Fluence Triple Therapy1/2 Fluence Double TherapyRanibizumabTotal
Mean58.1 ± 11.855.6 ± 11.253.3 ± 11.956.0 ± 13.155.7 ± 12.0
08

Study locations

26 sites
  • Mobile, Alabama, United States
  • Phoenix, Arizona, United States
  • Retina Centers, PC
    Tucson, Arizona, United States
  • Beverly Hills, California, United States
  • Campbell, California, United States
  • Los Angeles, California, United States
  • Poway, California, United States
  • Sacramento, California, United States
  • Torrance, California, United States
  • Fort Myers, Florida, United States
  • Indianapolis, Indiana, United States
  • Davenport, Iowa, United States
  • Missoula, Montana, United States
  • Omaha, Nebraska, United States
  • Portsmouth, New Hampshire, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • West Mifflin, Pennsylvania, United States
  • Arlington, Texas, United States
  • Temple, Texas, United States
  • Seattle, Washington, United States
  • Calgary, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Halifax, Nova Scotia, Canada
  • London, Ontario, Canada
  • Toronto, Ontario, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of May 2009 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2007
First posted
Jun 27, 2007
Start
Jul 2007
Primary completionActual
May 2009
CompletionActual
May 2010
Results first posted
Jun 22, 2010
Last update
Jun 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00492284
Lead sponsor
QLT Inc.
First posted
Jun 27, 2007
Start date
Jul 2007
Primary completion
May 2009
Completion
May 2010
Results posted
Jun 22, 2010
Last update
Jun 2, 2011

Study contacts

Henry Hudson, MD
principal investigator · Retina Centers, PC
Allen Ho, MD
principal investigator · Retina Diagnostic & Treatment Associates, LLC
Andrew Strong, Ph.D
study chair · QLT Inc.
Oscar Cuzzani, MD
study director · QLT Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion